The global immunoglobulins market was valued at USD 16.3 billion in 2022 and is projected to reach USD 27.7 billion by the end of 2031. This reflects a compound annual growth rate (CAGR) of 6.2% during the forecast period from 2023 to 2031. The market growth is driven by rising prevalence of immune deficiencies, autoimmune disorders, and increasing use of immunoglobulin therapies in neurological and chronic disease treatments, along with expanding healthcare access and advancements in biologic therapies.
Dive Deeper into
Data: Get Your In-Depth Sample Now! https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=52353
Market dynamics are currently centered on the "Home-Care
Transition." Survey data from early 2026 indicates that over 82% of
patients now prefer subcutaneous delivery over intravenous infusions,
citing the autonomy of home administration and a reduced travel burden. This
shift is being supported by insurers, as shifting patients to home settings can
avoid the high costs of hospital admissions for severe infections—often
exceeding US$ 122,000 per patient-year. However, the market remains
highly sensitive to Plasma Supply Constraints. Because production is
limited by the quantity of human plasma collected, vendors like CSL Behring
and Grifols are aggressively expanding fractionation capacities and
localized collection centers to mitigate supply-demand imbalances.
Technological innovation is pivoting toward Facilitated
SCIg and Digital Monitoring. In 2025 and 2026, the regulatory clearance of
therapies like HYQVIA for broader indications (including CIDP and
secondary immunodeficiency) has paved the way for "facilitated"
subcutaneous delivery, allowing for high-volume infusions that were previously
only possible intravenously. A key trend in 2026 is the integration of wearable
infusion devices and digital adherence tools, which allow clinicians
to monitor patient compliance and serum biomarker levels remotely. Furthermore,
advancements in recombinant and engineered antibodies are under
development, aiming to provide products with extended half-lives and reduced
systemic reactions.
The regional landscape is anchored by North America,
which held a dominant market share of approximately 46% in 2025. The
U.S. remains the largest single market, valued at US$ 11.6 billion,
driven by high awareness and a patient-centric reimbursement system. However, Asia-Pacific
is the fastest-growing region. Driven by rising healthcare spending in China
and India and a significant increase in the diagnosis of primary immunodeficiency
(PID), the region is scaling its domestic plasma fractionation infrastructure
to reduce long-term dependency on imports.
Key Findings of the Market Report
- Based
on route of administration, IVIG holds the largest current revenue
share, while SCIg is recording the fastest growth due to the
patient preference for home-based therapy.
- Primary
Immunodeficiency Disease (PID) remains the leading application
segment, accounting for approximately 26.3% of the market share in
early 2026.
- Neurological
Applications (e.g., CIDP and Myasthenia Gravis) are the
fastest-growing sub-sectors as more autoimmune indications receive
guideline support for maintenance dosing.
- Hospital
Pharmacies account for the majority of distribution share (57.3%),
but Specialty Pharmacies are capturing significant growth through
home-care delivery models.
Global Market: Growth Drivers
- Rising
Prevalence of Autoimmune Disorders: Growing incidences of CIDP, ITP,
and Kawasaki disease are driving steady demand for long-term antibody
replacement.
- Aging
Global Population: Older demographics are more susceptible to
secondary immunodeficiencies, increasing the long-term patient pool for Ig
therapies.
- Advancements
in Personalized Medicine: AI-driven diagnostic tools are helping
clinicians stratify patients for the most effective delivery routes and
dosing schedules.
- Government
Support for Rare Diseases: Expanded reimbursement and national
screening programs in emerging markets are identifying previously
undiagnosed PID patients.
Global Market: Key Players
Market leadership is highly concentrated, with the "Big
Three" (CSL, Takeda, and Grifols) controlling nearly 75% of the
global market through massive infrastructure investments.
- CSL
Behring (CSL Ltd.)
- Takeda
Pharmaceutical Company Limited
- Grifols
S.A.
- Octapharma
AG
- Kedrion
Biopharma
- Baxter
International Inc.
- GC
Biopharma (ALYGLO)
- ADMA
Biologics, Inc.
- China
Biologic Products Holdings
- LFB
Group
Global Market: Segmentation
By Route of Administration
- Intravenous
Immunoglobulin (IVIG)
- Subcutaneous
Immunoglobulin (SCIg)
- Intramuscular
Immunoglobulin (IMIG)
By Application
- Primary
Immunodeficiency (PID)
- Secondary
Immunodeficiency (SID)
- Chronic
Inflammatory Demyelinating Polyneuropathy (CIDP)
- Immune
Thrombocytopenic Purpura (ITP)
- Guillain-Barre
Syndrome
- Kawasaki
Disease
By Product Type
- IgG
(Most common)
- IgA
- IgM
- IgE
- IgD
By End-User
- Hospitals
and Clinics
- Homecare
Settings
- Ambulatory
Surgical Centers (ASCs)
Buy this Premium
Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=52353<ype=S
About
Transparency Market Research
Transparency
Market Research, a global market research company registered at Wilmington,
Delaware, United States, provides custom research and consulting services. Our
exclusive blend of quantitative forecasting and trends analysis provides
forward-looking insights for thousands of decision makers. Our experienced team
of Analysts, Researchers, and Consultants use proprietary data sources and
various tools & techniques to gather and analyses information.
Our
data repository is continuously updated and revised by a team of research
experts, so that it always reflects the latest trends and information. With a
broad research and analysis capability, Transparency Market Research employs
rigorous primary and secondary research techniques in developing distinctive
data sets and research material for business reports.
Contact:
Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Sales Inquiries: sales@transparencymarketresearch.com
Media Inquiries: media@transparencymarketresearch.com
0 Comments:
Post a Comment